Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 17/20 | 0.66 |
| ▸ | JAK2 | O60674 | 16/20 | 0.66 |
| ▸ | JAK3 | P52333 | 2/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26969038 | 1.00 | JAK1 (0.66) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL26078075 | 0.93 | JAK1 (0.66) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL29431262 | 0.93 | JAK1 (0.66) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL29170657 | 0.93 | JAK1 (0.66) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL24474633 | 0.93 | JAK1 (0.66) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL29431031 | 0.93 | JAK1 (0.66) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL26078074 | 0.93 | JAK1 (0.66) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL26078114 | 0.89 | JAK1 (0.66) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL29431122 | 0.88 | JAK1 (0.68) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL24474757 | 0.88 | JAK1 (0.68) | JAK1JAK2JAK3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630539-B2 | Amide compound, pharmaceutical composition and use thereof | ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| CN-114269736-B | Amide compound, pharmaceutical composition and application thereof | 科辉智药(深圳)新药研究中心有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230416237-A1 | AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) | 2023-12-28 | — | — | US | disclosed |
| EP-4253375-A1 | AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Artivila (ShenZhen) Innovation Center, Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| CN-114269736-A | Amide compound, pharmaceutical composition and application thereof | 深圳铂立健医药有限公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630539-B2 | Amide compound, pharmaceutical composition and use thereof | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885JAK3 3/4885 |
| US-20230416237-A1 | AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.